Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules
2024

Exemestane Schedules and Breast Tissue Drug Levels

Sample size: 180 publication 10 minutes Evidence: moderate

Author Information

Author(s): Davide Serrano, Harriet Johansson, Bjørn-Erik Bertelsen, Sara Gandini, Gunnar Mellgren, Parijatham Thomas, Katherine Crew, Nagi Kumar, Debora Macis, Valentina Aristarco, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Mauro D'Amico, Tania Buttiron-Webber, Irene Maria Briata, Stefano Spinaci, Viviana Galimberti, Lana A. Vornik, Eduardo Vilar, Powel H. Brown, Brandy M. Heckman-Stoddard, Eva Szabo, Bernardo Bonanni, Andrea DeCensi

Primary Institution: European Institute of Oncology IRCCS, Milan, Italy

Hypothesis

Can alternative schedules of exemestane effectively suppress estradiol levels in breast tissue for cancer prevention?

Conclusion

Exemestane taken once daily showed higher drug concentrations in nonmalignant breast tissue compared to other schedules, suggesting lower doses may be effective for cancer prevention.

Supporting Evidence

  • Exemestane and its metabolite levels were significantly higher in nonmalignant tissue in the daily dosing group.
  • Estradiol suppression was nearly complete in nonmalignant tissue across all dosing schedules.
  • A dose-response trend for estradiol was observed in malignant tissue.
  • Participants were treatment-compliant and well-balanced in age and BMI.
  • The study was approved by multiple institutional review boards.

Takeaway

This study looked at how different schedules of a breast cancer drug called exemestane affect hormone levels in breast tissue. It found that taking the drug every day works better than taking it less often.

Methodology

This was a presurgical, 3-arm, double-blind, phase IIb trial involving postmenopausal women with ER-positive breast cancer, comparing different dosing schedules of exemestane.

Potential Biases

The study was not powered to assess the impact of racial or ethnic differences.

Limitations

The study lacked samples from all participants and baseline tissue estradiol data due to limited biopsy material.

Participant Demographics

Out of 180 participants, 155 were White non-Hispanic postmenopausal women with ER-positive breast cancer.

Statistical Information

P-Value

<.0001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/jnci/djae183

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication